# Aptose Biosciences, Inc. (APTO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/APTO
## Company Profile
- Ticker: APTO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
- Tags: Oncology, Hematology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### Precision Hematology Company
Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.
### Tuspetinib Triplet
The TUSCANY study evaluates tuspetinib with venetoclax and azacitidine as a frontline regimen for newly diagnosed AML patients who are ineligible for intensive induction chemotherapy.
### Mutation-Agnostic Strategy
The triplet is intended to provide activity across a genetically diverse AML population without adding overlapping toxicities to the standard venetoclax and azacitidine backbone.
## Why The Stock Is Moving

Current closing-price context is not available for APTO.

## Future Catalysts

- Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.

## Drug Assets

- tuspetinib

## Recent News
- 2026-06-30 23:32 EST — [Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical](https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-completion-of-acquisition-by-hanmi-pharmaceutical-de9f8903) — Source: Aptose Biosciences, Inc.
- 2026-06-15 11:30 EST — [Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress  in Oral Presentation](https://biopharmsignal.com/news/APTO/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-cli-65fa124b) — Source: Aptose Biosciences, Inc.
- 2026-05-29 11:30 EST — [Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical](https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-update-on-anticipated-timing-of-closing-of-the-plan-17e05f74) — Source: Aptose Biosciences, Inc.
- 2026-05-13 21:00 EST — [Aptose Reports First Quarter 2026 Results](https://biopharmsignal.com/news/APTO/aptose-reports-first-quarter-2026-results) — Source: Aptose Biosciences, Inc.
- 2026-03-31 21:22 EST — [Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights](https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-results-of-special-shareholders-meeting-announces-receipt-of-final-court-approval-of-plan-of-arrangement-reports-year-end-2025-results-and-corporate-highlights) — Source: Aptose Biosciences, Inc.